Related Experiment Video
Updated: Apr 11, 2026

Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
A Case of Turmeric-Induced Hepatotoxicity with Hyperferritinemia
Nina R Spitofsky1, Albert A Huang1, Aria Jalalian2
1Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, USA.
Introduction:
We present the first published case of turmeric-associated drug-induced liver injury (DILI) accompanied by significant ferritin elevation.
Case Presentation:
Our patient, a 59-year-old female with DILI caused by long-term ingestion of oral turmeric supplements, presented with painless jaundice on an annual exam. The patient's liver function tests exhibited a hepatocellular pattern and hyperferritinemia (>2,000 ng/dL). Additional testing was negative except for heterozygosity for the H63D allele associated with hemochromatosis. A liver biopsy indicated acute hepatitis without fibrosis or stainable iron.
Conclusion:
Upon discontinuation of the supplement, liver enzymes normalized within a month. This case highlights the potential for hepatotoxicity and hyperferritinemia from curcumin toxicity, particularly when combined with additives like black pepper that enhance its bioavailability. Awareness of this phenomenon, particularly in heterozygous carriers of hemochromatosis, is crucial for diagnosis and optimal management.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Drug toxicity: Idiosyncratic Reactions
Drug toxicity: Drug–Drug Interaction

